Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?
AMA Journal of Ethics · 2023
DOI: 10.1001/amajethics.2023.478 ↗Kurz gefasst
Fachartikel in der Zeitschrift AMA Journal of Ethics, 2023. Verfasst von Astrid Floegel-Shetty. Beteiligte Einrichtung: Graduate of the Loyola Marymount University Bioethics Institute. Hauptthemen laut MEDLINE: Obesity, Weight Loss. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Ethically evaluating prescription of weight loss pharmaceuticals for adolescents classified by body mass index (BMI) as obese requires reconsideration of how medicine's overreliance on BMI as a diagnostic criterion supports a weight normative approach to health. This commentary on a case suggests that weight loss is not a safe, effective, or permanent method of health promotion. The unknown extent of pharmacotherapeutics' risks to adolescents in addition to the controvertible benefits of weight loss ethically preclude their prescription, despite scientific consensus to fight obesity by prescribing weight reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate of the Loyola Marymount University Bioethics Institute.
Zitieren
APA
Floegel-Shetty, A. (2023). Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?. AMA Journal of Ethics. https://doi.org/10.1001/amajethics.2023.478
Vancouver
Floegel-Shetty A. Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?. AMA Journal of Ethics. 2023. doi:10.1001/amajethics.2023.478
BibTeX
@article{FloegelShetty2023,
author = {Floegel-Shetty, Astrid},
title = {Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?},
journal = {AMA Journal of Ethics},
year = {2023},
doi = {10.1001/amajethics.2023.478}
}
EUVIMED